Crohn's Disease - Pipeline Assessment and Market Forecasts to 2017
Crohn's Disease - Pipeline Assessment and Market Forecasts to 2017
Report Reserve announces inclusion of a new market research report to its premium store.
GlobalData, the industry analysis specialist's new report, "Crohn's Disease Pipeline Assessment and Market Forecasts to 2017" is an essential source of information and analysis on the global Crohn's disease therapeutics market. The report identifies the key trends shaping and driving the global Crohn's disease therapeutics market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global Crohn's disease therapeutics sector.
The Crohn's Disease Therapeutics Market is Forecast to Show Modest Growth until 2017
GlobalData has estimated the global Crohn's disease therapeutics market to be valued at $2.8 billion in 2009. It is expected to grow to $4.7 billion with a Compound Annual Growth Rate (CAGR) of 6.6% by 2017. This growth is primarily attributed to the increased competition among the existing products and also the strong pipeline with more emerging therapies. The growth will be further supported by the increased uptake of biologics. The growth is attributed to the launches of the biologics which include Humira (Adalimumab), Cimzia (certolizumab pegol) and Tysabri (natalizumab).
Crohn's Disease Therapeutics Market, Global, Revenue and Market Forecast ($m), 20012017
Source: GlobalData, GlobalData Epidemiology-based Market Forecasting Model, Primary Research Interviews, Key Opinion Leader (KOL) Interviews
Competition in Crohn's Disease Therapeutics Market Becoming More Intense
GlobalData analyzed that the current competition in the Crohn's disease therapeutics market is becoming more intense due to the increased entry of biologics. Compared to other autoimmune disease markets, this market has witnessed the increased entry of biologics. Though only a small segmentation of people can use biologics, their launch has increased competition in the Crohn's disease therapeutics market. Johnson & Johnson's Remicade (infliximab) is the market leader and is followed by AstraZeneca/Prometheus's Entocort EC (budesonide), Biogen Idec's Tysabri (natalizumab) and Abbott's Humira (Adalimumab) respectively. There is increased competition between Remicade, Humira and the recently approved product Cimzia to be the market leader. Humira and Cimzia are presenting tough competition to Remicade, which has been in the market the longest. Tysabri has a different mechanism of action from these biologics, but its low safety record compared to other biologics is a concern. The global Crohn's disease therapeutics market has seen intense competition, which is expected to further intensify in the coming years.
Current Treatment Options are Moderately Successful in Meeting the Market Demand
GlobalData found that the available treatment options are moderately successful in meeting the market demand. Crohn's disease is a chronic condition. Current therapeutics are competing to provide a rapid induction of remission, maintenance of remission, and mucosal healing. Overall, there is competition to decrease the surgeries and hospitalizations. For people in the moderate to severe disease category, biologics are trying to provide better remission and reduce surgery. However, safety remains a concern. For people in the early stages, there is still a need for better therapy and therefore there is unmet need in the market. There is a market potential for any new entrant that can cater to the unmet need. There is enormous opportunity for any drug that would offer better results or retain the efficacy provided by the current players but with increased safety.
Opportunity and Unmet Need in the Crohn's Disease Therapeutics Market, 2010
Source GlobalData, GlobalData Epidemiology-based Market Forecasting Model, Primary Research Interviews, KOL Interviews
Emerging Therapies in Pipeline are Expected to Increase the Competition
GlobalData analyzed that there are over 49 molecules in various stages of the pipeline. Traficet-EN, Myoconda, MLN0002, Prochymal and Stelara are some of the late stage pipeline molecules. These pipeline molecules differ in their target of action from the existing therapies, and are likely to offer better safety. They are also likely to benefit patients who have become resistant to anti-Tumor Necrosis Factor (TNF)-alpha therapies.
The pipeline has seen an increase in the development of emerging therapies such as biologics as they have the ability to change the natural course of the disease. Emerging therapies have gained a positive perception among physicians in the maintenance of remission. There is likely to be a marginal increase in the prescription of biologics for long term maintenance as they have the capacity to avoid the need for steroids. The emerging therapies are likely to crowd the market and there seems to be the possibility of a price war. For more details, please vist http://www.reportreserve.com/reportdet.php?company=GlobalData&reportid=13187
Tips in Buying Venapro Hemorrhoids Formula ICD 10 Proves to be a Major Step Forward in Healthcare Software Blood Pressure Natural Remedies and High Blood Pressure Cure Taking Venapro Hemorrhoids Formula Common Symptoms Experienced During Pregnancy Pregnancy And Also Its Particular Presumptive Symptoms Illnesses That Can Instigate A Sleep Disorder Pregnancy And Its Typical Signs And Symptoms Frequent Symptoms Experienced Throughout Pregnancy The Beauty and Essence of Being in a Healthy Relationship Increasing Productivity And Helping Ease Back Pain With An Orthopaedic Chair Tips For Healthy Looking Eyes – What You Need To Ward Off Eye Wrinkles The Workings Of The Masters In Health Administration